Evidence map›Paper›PMID 29930274›Full record

ArticleNature chemistry2018

Cyclometallated ruthenium catalyst enables late-stage directed arylation of pharmaceuticals.

Marco Simonetti, Diego M Cannas, Xavier Just-Baringo, Iñigo J Vitorica-Yrezabal, Igor Larrosa

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Ligand-Enabled Stereoselective Coupling of Methylene C(spAngewandte Chemie (International ed. in English) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Improving the sustainability of the ruthenium-catalysedGreen chemistry : an international journal and green chemistry resource : GC · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Photo-Induced Ruthenium-Catalyzed Double Remote C(spAngewandte Chemie (International ed. in English) · 2022
    Article
  18. Pd(ii)-catalyzedChemical science · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marco SimonettiSchool of Chemistry, University of Manchester, Manchester, UK.
Diego M CannasSchool of Chemistry, University of Manchester, Manchester, UK.
Xavier Just-BaringoSchool of Chemistry, University of Manchester, Manchester, UK.
Iñigo J Vitorica-YrezabalSchool of Chemistry, University of Manchester, Manchester, UK.
Igor LarrosaSchool of Chemistry, University of Manchester, Manchester, UK. igor.larrosa@manchester.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biaryls are ubiquitous core structures in drugs, agrochemicals and organic materials that have profoundly improved many aspects of our society. Although traditional cross-couplings have made practical the synthesis of many biaryls, C-H arylation represents a more attractive and cost-effective strategy for building these structural motifs. Furthermore, the ability to install biaryl units in complex molecules via late-stage C-H arylation would allow access to valuable structural diversity, novel chemical space and intellectual property in only one step. However, known C-H arylation protocols are not suitable for substrates decorated with polar and delicate functionalities, which are commonly found in molecules that possess biological activity. Here we introduce a class of ruthenium catalysts that display a unique efficacy towards late-stage arylation of heavily functionalized substrates. The design and development of this class of catalysts was enabled by a mechanistic breakthrough on the Ru(II)-catalysed C-H arylation of N-chelating substrates with aryl (pseudo)halides, which has remained poorly understood for nearly two decades.

Indexed as

CatalysisCyclizationKineticsPharmaceutical PreparationsRutheniumPharmaceutical PreparationsRuthenium

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.